{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:22:27Z","timestamp":1785410547142,"version":"3.56.0"},"reference-count":20,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1533,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1111\/j.1528-1167.2011.03130.x","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T17:20:33Z","timestamp":1308676833000},"page":"1365-1371","source":"Crossref","is-referenced-by-count":30,"title":["Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy"],"prefix":"10.1111","volume":"52","author":[{"given":"Sara C.","family":"Erickson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Solow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen","family":"Zakharyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Stockl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.M.","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,6,21]]},"reference":[{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1528-1167.2007.01007.x","article-title":"Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes","volume":"48","author":"Andermann","year":"2007","journal-title":"Epilepsia"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/01.WNL.0000142091.47698.A2","article-title":"Lower phenytoin serum levels in persons switched from brand to generic phenytoin","volume":"63","author":"Burkhardt","year":"2004","journal-title":"Neurology"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1185\/03007990903488704","article-title":"Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs","volume":"26","author":"Devine","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1212\/WNL.0b013e3181aa5300","article-title":"The risks and costs of multiple-generic substitution of topiramate","volume":"72","author":"Duh","year":"2009","journal-title":"Neurology"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1528-1167.2008.01794.x","article-title":"Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study","volume":"50","author":"Faught","year":"2009","journal-title":"Epilepsia"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB7|cit7","volume-title":"Approved Drug Products With Therapeutic Equivalence Evaluations","author":"Food and Drug Administration Center for Drug Evaluation and Research","year":"2010"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1528-1167.2005.00403.x","article-title":"Mortality of epilepsy in developed countries: a review","volume":"46","author":"Forsgren","year":"2005","journal-title":"Epilepsia"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1212\/WNL.43.12.2696","article-title":"Carbamazepine toxicity resulting from generic substitution","volume":"43","author":"Gilman","year":"1993","journal-title":"Neurology"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1212\/01.wnl.0000313154.55518.25","article-title":"Clinical consequences of generic substitution of lamotrigine for patients with epilepsy","volume":"70","author":"LeLorier","year":"2008","journal-title":"Neurology"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1212\/01.wnl.0000259400.30539.cc","article-title":"Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy","volume":"68","author":"Liow","year":"2007","journal-title":"Neurology"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1212\/WNL.37.12.1885","article-title":"Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product","volume":"37","author":"MacDonald","year":"1987","journal-title":"Neurology"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.clinthera.2007.02.005","article-title":"Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy","volume":"29","author":"Makus","year":"2007","journal-title":"Clin Ther"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.yebeh.2008.12.006","article-title":"Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy","volume":"14","author":"Manjunath","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1081\/BIP-100104195","article-title":"Symmetry in square contingency tables: tests of hypotheses and confidence interval construction","volume":"11","author":"May","year":"2001","journal-title":"J Biopharm Stat"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1592\/phco.29.7.769","article-title":"Effects of antiepileptic drug substitutions on epileptic events requiring acute care","volume":"29","author":"Rascati","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB17|cit17","unstructured":"U.S. Food and Drug Administration 2009a What are generic drugs? http:\/\/www.fda.gov\/Drugs\/ResourcesForYou\/Consumers\/BuyingUsingMedicineSafely\/UnderstandingGenericDrugs\/ucm144456.htm"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB18|cit18","unstructured":"U.S. Food and Drug Administration 2009b Facts and myths about generic drugs http:\/\/www.fda.gov\/Drugs\/ResourcesForYou\/Consumers\/BuyingUsingMedicineSafely\/UnderstandingGenericDrugs\/ucm167991.htm"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jama.258.9.1216","article-title":"Increased seizure frequency with generic primidone","volume":"258","author":"Wyllie","year":"1987","journal-title":"JAMA"},{"key":"10.1111\/j.1528-1167.2011.03130.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1528-1167.2008.01703.x","article-title":"Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes","volume":"50","author":"Zachry","year":"2009","journal-title":"Epilepsia"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2011.03130.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1528-1167.2011.03130.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:02:08Z","timestamp":1625529728000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2011.03130.x"}},"subtitle":["Outcomes of Brand to Generic AED Switches"],"short-title":[],"issued":{"date-parts":[[2011,6,21]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03130.x","relation":{},"ISSN":["0013-9580"],"issn-type":[{"value":"0013-9580","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6,21]]}}}